Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEAPSAKE: Telaglenastat with Chemoimmunotherapy in KEAP1/NRF2-Mutated NSCLC
NCT04265534Phase 2Terminated
- Sponsor
- Calithera Biosciences
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) comparing Telaglenastat + SOC with Placebo + SOC (2 arms). Primary endpoints: Progression-Free Survival up to 24 months, Safety and Tolerability up to 55 months and 1 more. Started Jul 2020; status: terminated.
02
Drugs
telaglenastat
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04265534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265534.